上市委員會續置信保環球控股(00723.HK)於除牌程序第二階段 公司申覆核
信保環球控股(00723.HK)公布,在上周一(5月25日)接獲上市委員會函件,指上市委員會仍然不滿意公司業務之可行性及可持續性,決定維持上市部決定,將公司置於除牌程序第二階段。公司其後於上周五(5月29日)提出書面覆核要求。
上市委員會指,公司木材業務開展以來,其業務規模極小、毛利微薄及增值服務有限;放債業務開展以來,其規模細小,經考慮各項事宜如其小額及高度集中之貸款組合、持續依賴來自一名股東之貸款及依靠少量管理層成員以經營放債業務,其可行性及可持續性備受關注。
鑑於對木材業務及放債業務之可行性及可持續性之疑慮仍然存在,公司並未能證明其資產足以支持其營運。
股份續停牌。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.